Bristol-Myers Beat Estimates on Strong Hepatitis C Sales

Updated on
  • Drugmaker boosts 2016 EPS forecast to as much as $2.65
  • Hepatitis C revenue growth may be challenged by competition

Bristol-Myers Squibb Co. reported second-quarter earnings that beat analysts’ estimates partly on strong sales from its hepatitis C drugs, a segment that’s likely to face increased competition in the years ahead.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.